News

2013 Tribute Pharmaceuticals News Archive

Keyword Search
 
2015 | 2014 | 2013
DateTitle 
12/20/13CAMBIA(R) Update From Tribute Pharmaceuticals Dec 20
MILTON, ONTARIO -- (Marketwired) -- 12/20/13 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) (OTCBB:TBUFF) (PINKSHEETS:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today commented on the recent acquisition of CAMBIA® (diclofenac potassium for oral solution) by Depomed, Inc. (NASDAQ:DEPO). Depomed, Inc. ("Depomed") announced earlier this week that it had ... 
Printer Friendly Version
11/14/13Tribute Pharmaceuticals Announces Solid Growth in Third Quarter 2013 and Bezalip US IND Cleared by FDA
Milton, Ontario, Canada, November 14, 2013 – Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the “Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 third quarter ending September 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in a... 
Printer Friendly Version
11/11/13TRIBUTE PHARMA'S Investigational New Drug Application for Bezalip(R) SR Cleared by the US Food and Drug Administration
MILTON, ONTARIO -- (Marketwired) -- 11/11/13 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced that on September 27, 2013 an Investigational New Drug application ("IND") was submitted to the US Food and Drug Administration ("FDA") setting out the proposed development prog... 
Printer Friendly Version
08/09/13Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013
MILTON, ONTARIO -- (Marketwired) -- 08/09/13 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or "the Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 second quarter ending June 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted ... 
Printer Friendly Version
05/14/13Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013 May 14, 2013
MILTON, ONTARIO -- (Marketwired) -- 05/14/13 -- Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or "the Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 first quarter ending March 31, 2013. In this press release, all dollar amounts are expressed in Can... 
Printer Friendly Version
03/21/13Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth Mar 21, 2013
MILTON, ONTARIO -- (MARKETWIRE) -- 03/21/13 --Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF) ("Tribute" or "the Company"), a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).2012 Year-End Highlights:Reve... 
Printer Friendly Version
03/15/13Tribute Pharmaceuticals Expands Previously Announced Financing to Raise $4.6 Million
Raises an additional US$1,170,000Aggregate gross proceeds raised in the past 30 days of US$4.6 millionMILTON, ONTARIO -- (MARKETWIRE) -- 03/15/13 --Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or "the Company"), a Canadian specialty pharmaceutical company, today announced it has closed the second and final tranche of its privately placement of securities for aggregate gross proceeds of an additional US$1.2 million with private investors who are unaf... 
Printer Friendly Version
03/04/13Tribute Pharmaceuticals Raises $3,400,000 With Strong Participation from Board and Management
MILTON, ONTARIO -- (MARKETWIRE) -- 03/04/13 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or "the Company"), a Canadian specialty pharmaceutical company, today announced it has raised approximately US$3.4 million through a private placement with private investors including the Company's Chief Executive Officer, Chief Financial Officer and most members of its Board of Directors. Insiders' investments accounted for over 50% of the gross proceeds rai... 
Printer Friendly Version
01/02/13Stellar Pharmaceuticals Announces Name & Ticker Change to Tribute Pharmaceuticals Canada Inc. and 'TBUFF'; Issues Letter to Shareholders
MILTON, ONTARIO--(Marketwire - Jan. 2, 2013) - Stellar Pharmaceuticals Inc. (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF)(OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Stellar" or "the Company"), a Canadian specialty pharmaceutical company, today announced it has changed the Company's name to Tribute Pharmaceuticals Canada Inc. and it has been assigned a new ticker 'TBUFF'. The Company also issued a Letter to Shareholders.Highlights of the letter include:Effective January 2, 2013 the Company's na... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.